Krystal Biotech, Inc. KRYS Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s retained earnings?
- Krystal Biotech, Inc. (KRYS) reported retained earnings of $80.1M in Q1 2026.
- How has Krystal Biotech, Inc.'s retained earnings changed year-over-year?
- Krystal Biotech, Inc.'s retained earnings increased by 155.3% year-over-year, from -$144.94M to $80.1M.
- What is the long-term trend for Krystal Biotech, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s retained earnings has grown at a -19.4% compound annual growth rate (CAGR), from -$71.21M to $24.16M.
- What does retained earnings mean?
- The total profits the company has kept and reinvested since it started.
- How do you interpret retained earnings?
- A growing positive balance indicates profitability and self-funding capability, while a negative balance is common for pre-revenue or R&D-heavy firms.
- How does retained earnings compare across companies?
- Often negative for early-stage biotech companies; positive for mature, profitable pharmaceutical companies.